Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 301 of the 301 references it cites were found in a registry or an index; 179 of the 258 sources its claims cite were checked for support.

Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword

Open access

Abstract

Multiple myeloma (MM) is a hematological malignancy defined by the abnormal proliferation and accumulation of plasma cells (PC) within the bone marrow (BM). While multiple myeloma impacts the bone, it is not classified as a primary bone cancer. The bone marrow microenvironment significantly influences the progression of myeloma and its treatment response. Mesenchymal stromal cells (MSCs) in this environment engage with myeloma cells and other bone marrow components via direct contact and the secretion of soluble factors. This review examines the established roles of MSCs in multiple facets of MM pathology, encompassing their pro-inflammatory functions, contributions to tumor epigenetics, effects on immune checkpoint inhibitors (ICIs), influence on reprogramming, chemotherapy resistance, and senescence. This review investigates the role of MSCs in the development and progression of MM.

Overview

CoChat Summary

## TL;DR

This is a review of how mesenchymal stromal cells (MSCs) in the bone marrow niche can both support and restrain multiple myeloma (MM), with emphasis on tumor promotion, immune evasion, drug resistance, epigenetic change, and senescence. The authors argue that MSC-targeted strategies may be useful, but only with careful attention to MSC heterogeneity, safety, and the tumor microenvironment.

## Key findings

  • MM cells and bone marrow MSCs interact through direct contact and soluble factors, and this bidirectional crosstalk reshapes MSCs into MM-supportive cells with altered gene expression, epigenetic changes, senescence, and reprogramming.
  • MSCs contribute to MM progression through pro-inflammatory signaling, immune suppression, immune checkpoint pathways, angiogenesis, and chemoresistance; the review specifically highlights IL-6, VEGF, TGF-β, NF-κB, PI3K/AKT, and MAPK signaling.
  • The paper cites a study in which hypoxic bone marrow stromal cell-derived extracellular vesicles carried increased miR-140-5p and miR-28-3p and reduced bortezomib sensitivity in MM cells by targeting SPRED1 and increasing MAPK signaling.
  • It also cites a murine study where the dual inhibitor CM-272 prevented tumor-associated bone loss and reduced tumor burden in a myeloma model, and notes that iMSC signature expression correlated positively with minimal residual disease.

## Methods

  • This is a narrative review, not an original experimental study.
  • The authors report a comprehensive literature search of PubMed, Scopus, Web of Science, and Google Scholar from database inception to March 2024, using the keywords “Multiple myeloma,” “Bone marrow mesenchymal stromal cells,” and “Myeloma progression.”
  • Included studies were original English-language reports on MSC roles in MM pathology; conference abstracts, case reports, non-English papers, case series, and letters were excluded. Two researchers screened the literature independently and resolved disagreements by negotiation.

## Limitations

  • The paper states that many critical research areas remain insufficiently investigated, including MSC heterogeneity in the bone marrow niche, temporal evolution of MSC changes, and the roles of non-coding RNAs and extracellular vesicles.
  • It also notes that future work should use single-cell RNA sequencing, spatial transcriptomics, and longitudinal epigenetic profiling, implying that current evidence is limited by incomplete resolution of MSC subtypes and their spatial/temporal dynamics.
  • Evident from the text: because this is a review, it does not present new primary data, effect sizes, or a single unified meta-analytic estimate; conclusions depend on heterogeneous prior studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12935-025-03741-x

Cites

301 of 301 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Schematic representation of the interaction between Multiple Myeloma (MM) cells and Mesenchymal Stromal Cells (MSCs) in the bone marrow niche. This figure illustrates how MSCs influence MM progression through cytokine signaling, immune modulation, angiogenesis, and chemotherapy resistance
Fig. 1 Schematic representation of the interaction between Multiple Myeloma (MM) cells and Mesenchymal Stromal Cells (MSCs) in the bone marrow niche. This figure illustrates how MSCs influence MM progression through cytokine signaling, immune modulation, angiogenesis, and chemotherapy resistanceCC BY · PubMed Central

Verification

Claims the paper makes

123 Valid · 23 Not valid · 45 Not checked · 46 Own results and interpretations

98 more claims · 57 with their cited sources checked

Create a free account to see all 237 claims and to verify the 18 references still open.

See all claims — free account
  • It may state two separate claims as one. 110
  • Probably not a substantial claim. 35

Create a free account to see these claims.

Citations

Cites

Show all 298 references

Research works printed but not linked: 11

  1. García-Sánchez D et al. Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: impact on disease progression. 2023. 15(5): p. 421. · DOI · Paper page
  2. Giuliani N, Mangoni M, Rizzoli VJEh. Osteogenic Differ Mesenchymal Stem Cells Multiple Myeloma: Identif Potential Therapeutic Targets. 2009;37(8):879–86.
  3. Cippitelli M et al. Role of NF-κB signaling in the interplay between multiple myeloma and mesenchymal stromal cells. Int J Mol Sci, 2023. 24(3). · DOI · Paper page
  4. Dinmukhamedova AS, et al. Morphofunctional, hematological and biochemical indicators of First-Year students who came to study from urban and rural areas. Clin Schizophrenia Relat Psychoses. 2021;15(3):130521–130521.
  5. Khaniki MAL, Mirzaeibonehkhater M, Manthouri M. Enhancing Pneumonia Detection using Vision Transformer with Dynamic Mapping Re-Attention Mechanism. in 2023 13th International Conference on Computer and Knowledge Engineering (ICCKE). 2023.
  6. Hatami S, et al. The role of human Platelet-rich plasma in burn injury patients: A single center study. Canon J Med. 2023;4(2):41–5.
  7. Hatami S, et al. Evaluation the effect of lipofilling in burn Scar: A cross-sectional study. Canon J Med. 2023;4(3):78–82.
  8. Liu Z, et al. Immune checkpoint inhibitors for multiple myeloma immunotherapy. Exp Hematol Oncol. 2023;12(1):99. · DOI · Paper page
  9. Kanehira M, et al. An lysophosphatidic acid receptors 1 and 3 axis governs cellular senescence of mesenchymal stromal cells and promotes growth and vascularization of multiple myeloma. Stem Cells. 2017;35(3):739–53. · DOI · Paper page
  10. Fairfield H, et al. Multiple myeloma cells alter adipogenesis, increase senescence-related and inflammatory gene transcript expression, and alter metabolism in preadipocytes. Front Oncol. 2021;10:584683. · DOI · Paper page
  11. Liu H et al. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci Transl Med, 2019. 11(494). · DOI · Paper page

Cited by

See all 27

Metadata

Authors
Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H.
Affiliations
  • Guilan University of Medical Sciences (IR)
  • Tehran University of Medical Sciences (IR)
  • Iran University of Medical Sciences (IR)
  • Shahed University (IR)
  • Fasa University of Medical Sciences (IR)
  • Shahrekord University of Medical Sciences (IR)
  • Tarbiat Modares University (IR)
Corresponding author
  • Saeidi, Farzane
  • Ronaghi, Hossein
Venue
Cancer Cell International
Published
2025-03-26
Volume
25
Issue
1
Pages
117-117
ISSN
1475-2867 (ISSN-L)
OpenAlex
W4408851711
Cited by
27
References
298
Citations by year
2026: 19 · 2025: 8
FWCI
4.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer Cell International (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords
multiple myeloma, mesenchymal stem cells, bone marrow microenvironment, plasma cells, cancer epigenetics, immune checkpoint inhibitors, chemoresistance, cellular senescence, tumor reprogramming, myeloma progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword. https://app.cochat.ai/papers/10.1186/s12935-025-03741-x
The paper
Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025). Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword. Cancer Cell International. https://doi.org/10.1186/s12935-025-03741-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.